Literature DB >> 18931508

Heritability of lung function in severe alpha-1 antitrypsin deficiency.

D L DeMeo1, E J Campbell, M L Brantly, A F Barker, E Eden, N G McElvaney, S I Rennard, J M Stocks, J K Stoller, C Strange, G Turino, R A Sandhaus, E K Silverman.   

Abstract

Severe alpha-1 antitrypsin (AAT) deficiency is a proven genetic risk factor for COPD, but there is marked variation in the development of COPD among AAT deficient subjects. To investigate familial aggregation of lung function in subjects with AAT deficiency, we estimated heritability for forced expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity (FVC) in 378 AAT deficient subjects from 167 families in the AAT Genetic Modifiers Study; all subjects were verified homozygous for the Z AAT deficiency allele. Heritability was evaluated for models that included and excluded an ascertainment correction, as well as for models that excluded, included and were stratified by a cigarette smoking covariate. In models without an ascertainment correction, and in all models without a covariate for smoking, no evidence for familial aggregation of lung function was observed. In models conditioned on the index proband with covariates for smoking, post-bronchodilator FEV1/FVC demonstrated significant heritability (0.26 +/- 0.14, p = 0.03). When we limited the analysis to subjects with a smoking history, post-bronchodilator FEV1 demonstrated significant heritability (0.47 +/- 0.21, p = 0.02). Severity rate phenotypes were also assessed as potential phenotypes for genetic modifier studies. Significant heritability was found with all age-of-onset threshold models that included smoking and ascertainment adjustments. Using the t-distribution, the heritability estimates ranged from 0.43 to 0.64, depending on the age-of-onset of FEV1 decline used for the severity rate calculation. Correction for ascertainment and consideration of gene-by-smoking interactions will be crucial for the identification of genes that may modify susceptibility for COPD in families with AAT deficiency. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18931508     DOI: 10.1159/000164397

Source DB:  PubMed          Journal:  Hum Hered        ISSN: 0001-5652            Impact factor:   0.444


  8 in total

1.  The impact of single gene and chromosomal disorders on hospital admissions in an adult population.

Authors:  Danielle E Dye; Kate J Brameld; Susannah Maxwell; Jack Goldblatt; Peter O'Leary
Journal:  J Community Genet       Date:  2011-03-02

Review 2.  Why is Disease Penetration So Variable? Role of Genetic Modifiers of Lung Function in Alpha-1 Antitrypsin Deficiency.

Authors:  Brian D Hobbs; Michael H Cho
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

Review 3.  Recent advancements in understanding the genetic involvement of alpha-1 antitrypsin deficiency associated lung disease: a look at future precision medicine approaches.

Authors:  Auyon J Ghosh; Brian D Hobbs
Journal:  Expert Rev Respir Med       Date:  2022-01-13       Impact factor: 3.772

4.  Z α1-antitrypsin confers a proinflammatory phenotype that contributes to chronic obstructive pulmonary disease.

Authors:  Samuel Alam; Zhenjun Li; Carl Atkinson; Danny Jonigk; Sabina Janciauskiene; Ravi Mahadeva
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

Review 5.  Genes and chronic obstructive pulmonary disease.

Authors:  Marilyn G Foreman; Michael Campos; Juan C Celedón
Journal:  Med Clin North Am       Date:  2012-03-06       Impact factor: 5.456

6.  Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency.

Authors:  Woo Jin Kim; Alice M Wood; Alan F Barker; Mark L Brantly; Edward J Campbell; Edward Eden; Gerard McElvaney; Stephen I Rennard; Robert A Sandhaus; James M Stocks; James K Stoller; Charlie Strange; Gerard Turino; Edwin K Silverman; Robert A Stockley; Dawn L Demeo
Journal:  Respir Res       Date:  2012-02-22

Review 7.  Mysteries of α1-antitrypsin deficiency: emerging therapeutic strategies for a challenging disease.

Authors:  Raafe Ghouse; Andrew Chu; Yan Wang; David H Perlmutter
Journal:  Dis Model Mech       Date:  2014-04       Impact factor: 5.758

8.  The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes.

Authors:  Tomoko Nakanishi; Vincenzo Forgetta; Tomohiro Handa; Toyohiro Hirai; Vincent Mooser; G Mark Lathrop; William O C M Cookson; J Brent Richards
Journal:  Eur Respir J       Date:  2020-12-10       Impact factor: 16.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.